Lanthionine ketimine ester improves outcome in an MPTP-induced mouse model of Parkinson's disease via suppressions of CRMP2 phosphorylation and microglial activation

[1]  Y. Goshima,et al.  Genetic suppression of collapsin response mediator protein 2 phosphorylation improves outcome in methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced Parkinson’s model mice , 2018, Genes to cells : devoted to molecular & cellular mechanisms.

[2]  K. Hensley,et al.  Lanthionine ketimine ester promotes locomotor recovery after spinal cord injury by reducing neuroinflammation and promoting axon growth. , 2016, Biochemical and biophysical research communications.

[3]  Y. Goshima,et al.  Loss of collapsin response mediator protein 4 suppresses dopaminergic neuron death in an 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced mouse model of Parkinson's disease , 2016, Journal of neurochemistry.

[4]  D. Feinstein,et al.  Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis , 2015, Journal of neurochemistry.

[5]  R. Jope,et al.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. , 2015, Pharmacology & therapeutics.

[6]  G. Gao,et al.  Role of the Akt/GSK-3β/CRMP-2 pathway in axon degeneration of dopaminergic neurons resulting from MPP+ toxicity , 2015, Brain Research.

[7]  K. Mikoshiba,et al.  Cdk5/p35 is required for motor coordination and cerebellar plasticity , 2014, Journal of neurochemistry.

[8]  H. Okano,et al.  Rewiring of regenerated axons by combining treadmill training with semaphorin3A inhibition , 2014, Molecular Brain.

[9]  R. Niranjan.  The Role of Inflammatory and Oxidative Stress Mechanisms in the Pathogenesis of Parkinson’s Disease: Focus on Astrocytes , 2014, Molecular Neurobiology.

[10]  K. Hensley,et al.  A derivative of the brain metabolite lanthionine ketimine improves cognition and diminishes pathology in the 3 × Tg-AD mouse model of Alzheimer disease. , 2013, Journal of neuropathology and experimental neurology.

[11]  Robert E. Burke,et al.  Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.

[12]  P. Kaldis,et al.  Cdks, cyclins and CKIs: roles beyond cell cycle regulation , 2013, Development.

[13]  S. P. Singh,et al.  Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model , 2013, Neurochemistry International.

[14]  A. Bush,et al.  The effect of dopamine on MPTP-induced rotarod disability , 2013, Neuroscience Letters.

[15]  David S. Park,et al.  Conditional Disruption of Calpain in the CNS Alters Dendrite Morphology, Impairs LTP, and Promotes Neuronal Survival following Injury , 2013, The Journal of Neuroscience.

[16]  S. P. Singh,et al.  Neuroprotective Role of Withania somnifera Root Extract in Maneb–Paraquat Induced Mouse Model of Parkinsonism , 2013, Neurochemical Research.

[17]  K. Hensley,et al.  A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia , 2012, Neurochemistry International.

[18]  N. Ip,et al.  Cdk5: a multifaceted kinase in neurodegenerative diseases. , 2012, Trends in cell biology.

[19]  K. Mikoshiba,et al.  Phosphorylation of CRMP2 (Collapsin Response Mediator Protein 2) Is Involved in Proper Dendritic Field Organization , 2012, The Journal of Neuroscience.

[20]  T. Araki,et al.  ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation , 2011, Nature Cell Biology.

[21]  H. Okano,et al.  Beneficial compaction of spinal cord lesion by migrating astrocytes through glycogen synthase kinase-3 inhibition , 2011, Neuroscience Research.

[22]  N. Ip,et al.  Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease , 2011, Nature Cell Biology.

[23]  K. Hensley,et al.  Emerging Biological Importance of Central Nervous System Lanthionines , 2010, Molecules.

[24]  S. Kitazawa,et al.  A rotarod test for evaluation of motor skill learning , 2010, Journal of Neuroscience Methods.

[25]  R. Burke,et al.  Clinical progression in Parkinson disease and the neurobiology of axons , 2010, Annals of neurology.

[26]  K. Hensley,et al.  Proteomic Identification of Binding Partners for the Brain Metabolite Lanthionine Ketimine (LK) and Documentation of LK Effects on Microglia and Motoneuron Cell Cultures , 2010, The Journal of Neuroscience.

[27]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[28]  Robert A. Hauser,et al.  Levodopa: Past, Present, and Future , 2008, European Neurology.

[29]  A. Verkhratsky,et al.  Collapsin response mediator protein‐2 hyperphosphorylation is an early event in Alzheimer’s disease progression , 2007, Journal of neurochemistry.

[30]  David S. Park,et al.  Role of Cdk5-Mediated Phosphorylation of Prx2 in MPTP Toxicity and Parkinson's Disease , 2007, Neuron.

[31]  S. Tufik,et al.  The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. , 2007, European journal of pharmacology.

[32]  H. Okano,et al.  A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord , 2006, Nature Medicine.

[33]  B. Bu,et al.  Suppression of astroglial scar formation and enhanced axonal regeneration associated with functional recovery in a spinal cord injury rat model by the cell cycle inhibitor olomoucine , 2006, Journal of neuroscience research.

[34]  David S. Park,et al.  Calpain-Regulated p35/cdk5 Plays a Central Role in Dopaminergic Neuron Death through Modulation of the Transcription Factor Myocyte Enhancer Factor 2 , 2006, The Journal of Neuroscience.

[35]  T. Südhof,et al.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[37]  David S. Park,et al.  Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease , 2004, The Journal of Neuroscience.

[38]  David S. Park,et al.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  K. Tamayose,et al.  An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Ishiguro,et al.  Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons. , 1998, Biochemical and biophysical research communications.

[41]  L. Tsai,et al.  p35, the Neuronal-specific Activator of Cyclin-dependent Kinase 5 (Cdk5) Is Degraded by the Ubiquitin-Proteasome Pathway* , 1998, The Journal of Biological Chemistry.

[42]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[43]  O. Hornykiewicz.  L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent , 2002, Amino Acids.